CD8A and non-small cell lung carcinoma: In a phase III clinical trial for non-small cell lung cancer (NSCLC), a gene signature of CD39 + CD8 + T cells was shown to predict the benefit from immune checkpoint blockade (ICB) but not chemotherapy.